{"id":1342,"date":"2023-10-26T14:39:46","date_gmt":"2023-10-26T14:39:46","guid":{"rendered":"https:\/\/fhucare2.laurent-angeli.fr\/event\/assemblee-generale-fhu-care-2024\/"},"modified":"2025-12-26T01:55:34","modified_gmt":"2025-12-26T00:55:34","slug":"assemblee-generale-fhu-care-2024","status":"publish","type":"post","link":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/event\/assemblee-generale-fhu-care-2024\/","title":{"rendered":"Assembl\u00e9e G\u00e9n\u00e9rale FHU CARE 2024"},"content":{"rendered":"<p><span style=\"font-family: tahoma, arial, helvetica, sans-serif\"><span style=\"font-size: 14pt;background-color: #ffffff\"><span style=\"font-size: 18pt\">PROGRAMME AG FHU CARE<\/span><br \/><strong><span style=\"color: #333399\">Lundi 29 janvier 2024 (14h-17h)&nbsp;<\/span><br \/><\/strong><\/span><span style=\"background-color: #ffffff\"><span style=\"font-size: 14pt\">H\u00f4pital Bic\u00eatre,&nbsp;<\/span><span style=\"font-size: 14pt\">B\u00e2timent Barr\u00e9-Sinoussi <br \/><span style=\"font-size: 12pt\">Secteur Orange, porte 40, RdC salle Staff (plan plus bas)<\/span><\/span><\/span><\/span><\/p>\n<p style=\"text-align: justify\"><span style=\"font-size: 10pt;background-color: #99ccff;font-family: tahoma, arial, helvetica, sans-serif\">Format pour chaque slot : 8-10 mn de pr\u00e9sentation&nbsp; + 5 mn Q&amp;R<\/span><\/p>\n<p><span style=\"color: #333399;font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\"><strong><strong>14.00&nbsp;:&nbsp;<\/strong>Introduction<\/strong> et <strong>avancements<\/strong>&nbsp;de <strong>FHU CARE<\/strong> (I et II) et&nbsp;<a href=\"https:\/\/dim-itac.com\/en\/\"><strong>DIM ITAC <\/strong><\/a>par <strong>Xavier Mariette&nbsp;<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-family: tahoma, arial, helvetica, sans-serif;font-size: 10pt\"><strong>FHU CARE II<\/strong> : Perspectives et pr\u00e9paration de la seconde \u00e9dition de la FHU en lien avec le DIM ITAC par <strong>Xavier Mariette<\/strong><\/span><\/li>\n<li><span style=\"font-family: tahoma, arial, helvetica, sans-serif;font-size: 10pt\">Pr\u00e9sentation du projet Club Immunoth\u00e9rapie Intensive et MAI&nbsp;par <strong>Xavier Mariette<\/strong><\/span><\/li>\n<li><span style=\"font-family: tahoma, arial, helvetica, sans-serif;font-size: 10pt\">CAR-T cell \u00e0 Gustave Roussy et collaboration pour traiter les maladies auto-immunes (FHU CARE II) par&nbsp;<strong>Camille Bigenwald<\/strong><\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif;color: #333399\"><a href=\"en\/work-packages\/common-pathways-involved-in-autoimmune-diseases-cancer-and-inflammatory-diseases\" target=\"_blank\" rel=\"noopener\" style=\"background-color: #ffffff;color: #333399\"><strong>WP1 : Common and opposite mechanisms involved in AID and cancer<\/strong><\/a><span><\/span><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">Programme MELAVATAR (Johns Hopkins University) par <strong>Samad Mohammadnezhaddaryani&nbsp;<\/strong>en connection avec la BDD melanome Gustave Roussy par&nbsp;<strong>Caroline Robert<\/strong><\/span><\/li>\n<li><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">Update sur les Immuno-organoides de glande salivaire, mod\u00e8le d&rsquo;\u00e9tude du Sjogren par&nbsp;<strong>Lo\u00efc Meudec<\/strong>&nbsp;,&nbsp;<strong>Negaar Goudarzi <\/strong>et<strong> Gaetane Nocturne<\/strong><\/span><\/li>\n<li><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">Anti-Inflammatory biotherapies and Cancer : the Ying and the Yang (ABICAY) &#8211; impact of JAKi on macrophages cells par <strong>Audrey Paoletti<\/strong><\/span><\/li>\n<li><span style=\"font-family: tahoma, arial, helvetica, sans-serif;font-size: 10pt\"><a href=\"fr\/research-projects\/tnf-sen-opposite-mechanisms-senescent-t-cells-in-cancer-and-in-autoimmune-diseases\">TNFSEN<\/a>&nbsp;Senescence &gt; Maladies auto-immunes et s\u00e9nescence lymphocytaire&nbsp;par <strong>Matthieu Roulleaux Dugage&nbsp;<\/strong>et&nbsp;<strong>Samuel Bitoun<\/strong><\/span>&nbsp;<\/li>\n<\/ul>\n<p><span style=\"background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\"><strong><span style=\"font-size: 10pt\"><a href=\"en\/work-packages\/auto-immunity-and-inflammation-are-risk-factors-of-cancer\" target=\"_blank\" rel=\"noopener\" style=\"background-color: #ffffff\"><span style=\"color: #333399\">WP2 : Auto immunity as a risk factor of Cancer&nbsp;<\/span><\/a><\/span><\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-family: tahoma, arial, helvetica, sans-serif\"><span style=\"font-size: 10pt;background-color: #ffffff\">Nouvelles datas de la litt\u00e9rature sur RTX et risque de cancers par <strong>Rapha\u00e8le Seror<\/strong> et le projet d\u2019\u00e9tude qui d\u00e9marre avec <strong>Florence Tubachs<\/strong><\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif;color: #333399\"><strong>Coffee&nbsp;break 15min<\/strong><em><\/em><\/span><\/p>\n<p><span style=\"color: #333399;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\"><strong><span style=\"font-size: 10pt\"><a href=\"en\/work-packages\/immune-related-adverse-events-iraes-in-the-immunotherapy-of-cancer\" style=\"color: #333399;background-color: #ffffff\">WP3 : Risk of Autoimmunity after ICI&nbsp;<\/a><\/span><\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">Update PREMIS par <span style=\"font-size: 10pt\"> <strong>Nathalie Chaput-Gras ,<\/strong>&nbsp;<\/span><strong><strong>Aur\u00e9lien Marabelle <\/strong><\/strong>et<strong><strong> Fran\u00e7ois-Xavier Danlos<\/strong><\/strong><\/span><\/li>\n<li><span style=\"font-size: 13.3333px;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">CITAR&nbsp;Checkpoint Inhibitors Treatment ARthritis&nbsp;<span style=\"font-size: 13.3333px;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">(tocilizumab VS corticosteroids)<\/span> par <strong>Samuel Bitoun<\/strong><\/span><\/li>\n<li><span style=\"font-size: 10pt;font-family: tahoma, arial, helvetica, sans-serif\">King&rsquo;s College London &amp; Gustave Roussy collaboration &gt; OST toxicity score by <strong>Matthaios Kapiris&nbsp;<\/strong><\/span><\/li>\n<\/ul>\n<p><span style=\"background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\"><strong><span style=\"font-size: 10pt\"><a href=\"en\/work-packages\/teaching-the-relation-between-auto-immunity-and-cancer\" target=\"_blank\" rel=\"noopener\" style=\"background-color: #ffffff\"><span style=\"color: #333399\">&nbsp;WP4&nbsp;: Education<\/span><\/a><\/span><\/strong><\/span><\/p>\n<ul>\n<li><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">E-learning SPOC EUGLOH MIR<span style=\"color: #000000\">ACIP &gt;&gt;<strong>2nde \u00e9dition<\/strong> :&nbsp;<strong><a href=\"https:\/\/www.medecine.universite-paris-saclay.fr\/en\/spoc-miracip\" target=\"_blank\" rel=\"noopener\" style=\"background-color: #ffffff;color: #000000\">Management of immunorelated complication of cancer immunotherapy<\/a><\/strong> par <strong>Olivier Lambotte <\/strong>et&nbsp;<strong><strong>Samuel Bitoun<\/strong><\/strong> et<strong><strong> Bertrand Bech<\/strong><\/strong><\/span><\/span><\/li>\n<li><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">SPOC MIRACIP &gt;&gt;<strong><span style=\"color: #000000\">3\u00e8me \u00e9dition<\/span><\/strong>&nbsp;: am\u00e9liorer l&rsquo;attractivit\u00e9 &gt; SPOC MIRACIP <span style=\"text-decoration: underline\">#industriels<\/span> &gt; cf Aur\u00e9lien Marabelle + Directeur des Soins de Gustave Roussy + UniCancer.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 10pt;background-color: #ffffff;font-family: tahoma, arial, helvetica, sans-serif\">17.00&nbsp;: FIN de l\u2019AG FHU CARE.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/fhucare2.laurent-angeli.fr\/wp-content\/uploads\/2025\/12\/plan-hopital-bictre.jpg\" width=\"1200\" height=\"1697\" alt=\"plan hopital bictre\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PROGRAMME AG FHU CARELundi 29 janvier 2024 (14h-17h)&nbsp;H\u00f4pital Bic\u00eatre,&nbsp;B\u00e2timent Barr\u00e9-Sinoussi Secteur Orange, porte 40, RdC salle Staff (plan plus bas) Format pour chaque slot : 8-10 mn de pr\u00e9sentation&nbsp; + 5 mn Q&amp;R 14.00&nbsp;:&nbsp;Introduction et avancements&nbsp;de FHU CARE (I et II) et&nbsp;DIM ITAC par Xavier Mariette&nbsp; FHU CARE II : Perspectives et pr\u00e9paration de la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1343,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"event_date":"Lundi 29 janvier 2024","event_location":"H\u00f4pital Bic\u00eatre  B\u00e2timent Barr\u00e9-Sinoussi  Secteur Orange, porte 40 RDC salle Staff","event_time":"de 14h00 \u00e0 17h00","footnotes":""},"categories":[10],"tags":[],"class_list":["post-1342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-event"],"_links":{"self":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/comments?post=1342"}],"version-history":[{"count":3,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1342\/revisions"}],"predecessor-version":[{"id":2488,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/posts\/1342\/revisions\/2488"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/media\/1343"}],"wp:attachment":[{"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/media?parent=1342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/categories?post=1342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fhucare2.laurent-angeli.fr\/fr\/wp-json\/wp\/v2\/tags?post=1342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}